A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps

Healthy Volunteers: Inclusion Criteria: * Healthy males and females witha BMI between 18.0 and 32.0 kg/m2, inclusive Exclusion Criteria: * subject with evidence of a clinically significant disorder, condition or disease that would pose a risk to subject safety or interfere with study evaluation, procedures, or completion. Subjects with chronic rhinosinusitis with nasal polyps (CRSwNP): Inclusion Criteria: * diagnosis of CRSwNP (inflammation of the nose and paranasal sinuses characterized in adults by 2 or more symptoms, 1 of which should be either nasal blockage or nasal discharge and/or facial pain and/or reduced smell for greater than 12 weeks) * bilateral nasal polyps of grade 3 or 4 Exclusion Criteria: * Forced Expiratory Volume (FEV1) \</= 70% * Asthma exacerbation requiring systemic corticosteroid treatment or hospitalization for \> 24h for treatment of asthma, within 3 months prior to screening or are on a dose of greater than 1000 μg fluticasone.